医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SuperSonic Imagine Has Signed the Exclusive Distribution Agreement with Konica Minolta

2015年01月29日 AM06:15
このエントリーをはてなブックマークに追加


 

AIX-EN-PROVENCE, France

SuperSonic Imagine (Euronext : SSI, FR0010526814), a company specializing in ultrasound medical imaging equipment, announces the signing of an exclusive partnership with Konica Minolta, Inc. (Konica Minolta) to distribute its ultrasound system, the Aixplorer®, in Japan.

This partnership significantly increases SuperSonic Imagine’s geographical coverage. Japan is the third largest ultrasound market in the world and is a key part of the company’s global expansion strategy.

We are very pleased to include SuperSonic Imagine’s Aixplorer ultrasound system in our portfolio of medical imaging solutions. The Aixplorer surpasses the limits of traditional ultrasound.” said Keijiro Asayama General Manager, Ultrasound Business Unit from Konica Minolta. ”Its pioneering technology is in alignment with our own company mission to provide innovative, high quality products to our customers.”

SuperSonic Imagine’s Aixplorer is unique with its UltraFast™ software platform which can acquire images 200 times faster than conventional ultrasound systems. The speed of the UltraFast platform enables SuperSonic Imagine’s proprietary ShearWave™ Elastography technology to assess and quantify tissue stiffness in real time. Tissue stiffness is used by physicians to help identify potentially malignant or other diseased tissue.

“SuperSonic Imagine is very proud to be working with Konica Minolta, a prestigious company and ideal partner for expanding the use of our ultrasound technology in Japan.” said Jacques Souquet, Founder and CEO of SuperSonic Imagine, “Our technology provides detailed, real-time information important to the Japanese general imaging marketplace and can be used in a broad range of applications such as breast, thyroid, liver and musculoskeletal exams.”

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com

CONTACT

SuperSonic Imagine
Marketing & Communication
Emmanuelle
Vella
emmanuelle.vella@supersonicimagine.com
04
86 79 03 27
or
NewCap
Investor Relations
Pierre
Laurent / Florent Alba
supersonicimagine@newcap.fr
01
44 71 98 55
or
ComCorp
Media Relations
Florence
Portejoie
fportejoie@comcorp.fr
01
58 18 32 58 – 06 88 84 81 74
Adelaïde Manester
amanester@comcorp.fr
01
58 18 32 58 – 06 70 45 74 37

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates